Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Spondylitis, Ankylosing 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Pneumonia 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1COVID-19 1Arthritis, Rheumatoid 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × tocilizumab × Clear all
NCT05769959 2024-07-09

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
3 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡